Want to see AU:ADO full AI Analyst Report?
ADO Stock Chart & Stats
AU$0.02
>-AU$0.01(-5.00%)
At close: 4:00 PM EST
AU$0.02
>-AU$0.01(-5.00%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.05
Previous CloseN/A
Volume1.67M
Average Volume (3M)1.47M
Market Cap
AU$78.23M
Enterprise ValueAU$99.20M
Total Cash (Recent Filing)AU$1.44M
Total Debt (Recent Filing)AU$2.85M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,259,767,300
10 Day Avg. Volume1,501,441
30 Day Avg. Volume1,471,917
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)10.79
Price to Sales (P/S)35.07
P/FCF Ratio-5.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$2.80M
Bulls Say, Bears Say
Bulls Say
Proprietary Surface-chemistry TechnologyAnteoTech's proprietary surface functionalisation IP targets diagnostics and battery materials, creating durable technical barriers and differentiation. This IP can drive long-term product adoption, licensing, and partner lock-in across multiple high-growth end markets, supporting sustainable competitive advantage.
Multiple Monetization PathwaysA business model that combines product sales, licensing, paid development work and grants diversifies revenue timing and reduces reliance on one channel. Structurally, this mix supports recurring royalties, milestone-driven inflows and scalable product revenue as partners validate and adopt the technology.
Manageable Financial LeverageA moderate debt-to-equity ratio provides financial flexibility and lower near-term refinancing pressure compared with high-leverage peers. This manageable leverage supports continued investment in commercialization and R&D, assuming operational improvements, and reduces immediate solvency risk over the medium term.
Bears Say
Persistent Losses And Negative MarginsConsistent negative net, EBIT and EBITDA margins indicate the company is not yet profitable at scale. Persistent losses erode equity, increase dependence on external capital, and make executing long-term commercialisation plans harder without clear path to margin improvement and operational efficiency gains.
Negative Operating And Free Cash FlowOngoing negative operating and free cash flows signal cash burn that limits self-funding of growth and commercialization. Structural reliance on external financing increases dilution risk, constrains timely scale-up of manufacturing or sales, and raises execution risk if partner payments or grants are delayed.
Sharp Revenue Volatility And Recent Steep DeclineHigh revenue volatility and extreme recent declines undermine forecasting, partner confidence and capital allocation. For a tech-commercialisation business, erratic revenues slow scale economics, complicate long-term contracts and make it harder to justify sustained investments in production or sales infrastructure.
AnteoTech Ltd News
ADO FAQ
What was AnteoTech Ltd’s price range in the past 12 months?
AnteoTech Ltd lowest share price was AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is AnteoTech Ltd’s market cap?
AnteoTech Ltd’s market cap is AU$78.23M.
When is AnteoTech Ltd’s upcoming earnings report date?
AnteoTech Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 43 days.
How were AnteoTech Ltd’s earnings last quarter?
AnteoTech Ltd released its earnings results on Feb 24, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AnteoTech Ltd overvalued?
According to Wall Street analysts AnteoTech Ltd’s price is currently Overvalued.
Does AnteoTech Ltd pay dividends?
AnteoTech Ltd does not currently pay dividends.
What is AnteoTech Ltd’s EPS estimate?
AnteoTech Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AnteoTech Ltd have?
AnteoTech Ltd has 3,259,767,300 shares outstanding.
What happened to AnteoTech Ltd’s price movement after its last earnings report?
AnteoTech Ltd reported an EPS of AU$0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of AnteoTech Ltd?
Currently, no hedge funds are holding shares in AU:ADO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AnteoTech Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ADO Sentiment 96%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth AU$86.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.00%
12-Months-Change
Fundamentals
Return on Equity
-142.30%
Trailing 12-Months
Asset Growth
-58.00%
Trailing 12-Months
Company Description
AnteoTech Ltd
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
Technical Analysis
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Proteomics International Laboratories Ltd.
―
Radiopharm Theranostics Limited
―